Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Prospective Challenges for Patenting and Clinical Trials of Anticancer Compounds from Natural Products: Coherent Review

Author(s): Ankit Sahoo, Ashok Kumar Mandal, Mayank Kumar, Khusbu Dwivedi and Deepika Singh*

Volume 18, Issue 4, 2023

Published on: 15 November, 2022

Page: [470 - 494] Pages: 25

DOI: 10.2174/1574892818666221104113703

Price: $65

Abstract

Cancer is a leading cause of morbidity and mortality worldwide. Each year, millions of people worldwide are diagnosed with cancer, and more than half of them die. Various conventional therapies for cancer, including chemotherapy and radiotherapy, have extreme side effects. Therefore, to minimize the global burden of lethal diseases like cancer, an effective and novel drug must be discovered. Its patent should be acquired to secure the novel medicament. The pharmacological potential of different natural products has made them popular in the healthcare and pharmaceutical industries. Various anticancer compounds are obtained from natural sources such as plants, microbes, and marine and terrestrial animals, including alkaloids, terpenoids, biophenols, enzymes, glycosides, etc. The term "natural products" is defined as the product of secondary or non-essential metabolic processes produced by living organisms (such as plants, invertebrates, and microorganisms). Although more precise definitions of NPs exist, they do not always meet consensus. Others define NPs as small molecules (excluding biomolecules) that emerge from the metabolic reaction. A handful of effective compounds are used currently from natural or analog moieties, and many more are in clinical studies. There is an excellent need for patenting molecules from natural products as the hit lead molecules are derived, isolated, and synthesized from natural products. However, these naturally occurring products may not be patentable under the law because they come from nature. This review highlights why natural products and compounds are hard to patent, under what patent law criteria we can patent these natural products and compounds, patent procedural guideline sources and why researchers prefer publication rather than a patent. Here, various patent scenarios of natural products and compounds for cancer have been given.

Keywords: Natural products, anticancer compounds, patent, clinical trial, marketed product, radiotherapy, chemotherapy.

« Previous Next »
[1]
Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract 2016; 25(S2): 41-59.
[http://dx.doi.org/10.1159/000443404] [PMID: 26679767]
[2]
Correa CM, Reto MH, Eds. Access to Medicines and Vaccines. Switzerland AG: Springer Nature 2012; pp. 1-373.
[3]
Sharifi-Rad J, Ozleyen A, Boyunegmez Tumer T, et al. Natural products and synthetic analogs as a source of antitumor drugs. Biomolecules 2019; 9(11): 697.
[http://dx.doi.org/10.3390/biom9110679] [PMID: 31683894]
[4]
Amin A, Lotfy M, Mahmoud-Ghoneim D, et al. Pancreas-protective effects of chlorella in STZ-induced diabetic animal model: insights into the mechanism. J Diabetes Mellitus 2011; 1(3): 36-45.
[http://dx.doi.org/10.4236/jdm.2011.13006]
[5]
Al Shamsi M, Amin A, Adeghate E. Vitamin E ameliorates some biochemical parameters in normal and diabetic rats. Ann N Y Acad Sci 2006; 1084(1): 411-31.
[http://dx.doi.org/10.1196/annals.1372.033] [PMID: 17151319]
[6]
Al Shamsi MS, Amin A, Adeghate E. Beneficial effect of vitamin E on the metabolic parameters of diabetic rats. Mol Cell Biochem 2004; 261(1): 35-42.
[http://dx.doi.org/10.1023/B:MCBI.0000028735.79172.9b] [PMID: 15362483]
[7]
Shamsi MA, Amin A, Adeghate E. Effect of vitamin C on liver and kidney functions in normal and diabetic rats. Ann N Y Acad Sci 2006; 1084(1): 371-90.
[http://dx.doi.org/10.1196/annals.1372.031] [PMID: 17151316]
[8]
EL-Dakhly SM, Salama AAA, Hassanin SOM, Yassen NN, Hamza AA, Amin A. Aescin and diosmin each alone or in low dose- combination ameliorate liver damage induced by carbon tetrachloride in rats. BMC Res Notes 2020; 13(1): 259.
[http://dx.doi.org/10.1186/s13104-020-05094-2] [PMID: 32460808]
[9]
Murali C, Mudgil P, Gan CY, et al. Camel whey protein hydrolysates induced G2/M cellcycle arrest in human colorectal carcinoma. Sci Rep 2021; 11(1): 7062.
[http://dx.doi.org/10.1038/s41598-021-86391-z] [PMID: 33782460]
[10]
Al-Dabbagh B, Elhaty IA, Murali C, Madhoon AA, Amin A. Salvadora persica (Miswak): antioxidant and promising antiangiogenic insights. Am J Plant Sci 2018; 9(6): 1228-44.
[http://dx.doi.org/10.4236/ajps.2018.96091]
[11]
Hamza AA, Lashin FM, Gamel M, Hassanin SO, Abdalla Y, Amin A. Hawthorn herbal preparation from crataegus oxyacantha attenuates in vivo carbon tetrachloride-induced hepatic fibrosis via modulating oxidative stress and inflammation. Antioxidants 2020; 9(12): 1173.
[http://dx.doi.org/10.3390/antiox9121173] [PMID: 33255507]
[12]
Hamza AA, Mohamed MG, Lashin FM, Amin A. Dandelion prevents liver fibrosis, inflammatory response, and oxidative stress in rats. J Basic Appl Zool 2020; 81(1): 1-13.
[13]
Amin A, Mahmoud-Ghoneim D. Texture analysis of liver fibrosis microscopic images: a study on the effect of biomarkers. Acta Biochim Biophys Sin 2011; 43(3): 193-203.
[http://dx.doi.org/10.1093/abbs/gmq129] [PMID: 21258076]
[14]
Li Rl, Zhang Q. Liu l, et al. Processing methods and mechanisms for alkaloid-rich Chinese herbal medicines: A review. J Integr Med 2021; 19(2): 89-103.
[15]
Li J, Liang Q, Sun G. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: A focus on epithelial-mesenchymal transition. J Integr Med 2021; 19(6): 469-77.
[http://dx.doi.org/10.1016/j.joim.2021.08.004] [PMID: 34538644]
[16]
Tallmadge EH. Patenting natural product after Myrid. Vol. 30, Massachusttus. Harv J Law Technol 2017; 569-98.
[17]
Nazarbek G, Kutzhanova A, Nurtay L, et al. Nano-evolution and protein-based enzymatic evolution predicts novel types of natural product nanozymes of traditional Chinese medicine: cases of herbzymes of Taishan-Huangjing (Rhizoma polygonati) and Goji (Lycium chinense). Nanoscale Adv 2021; 3(23): 6728-38.
[http://dx.doi.org/10.1039/D1NA00475A] [PMID: 36132653]
[18]
Hanna EM, Zaki N, Amin A. Detecting protein complexes in protein interaction networks modeled as gene expression biclusters. PLoS One 2015; 10(12): e0144163.
[http://dx.doi.org/10.1371/journal.pone.0144163] [PMID: 26641660]
[19]
Mu C, Sheng Y, Wang Q, Amin A, Li X, Xie Y. Potential compound from herbal food of Rhizoma Polygonati for treatment of COVID-19 analyzed by network pharmacology: Viral and cancer signaling mechanisms. J Funct Foods 2021; 77: 104149.
[http://dx.doi.org/10.1016/j.jff.2020.104149] [PMID: 32837538]
[20]
Xie Y, Mu C, Kazybay B, et al. Network pharmacology and experimental investigation of Rhizoma polygonati extract targeted kinase with herbzyme activity for potent drug delivery. Drug Deliv 2021; 28(1): 2187-97.
[http://dx.doi.org/10.1080/10717544.2021.1977422] [PMID: 34662244]
[21]
Sherkow JS. The natural complexity of patent eligibility. Iowa Law Rev 2014; 99(3): 1137-96.
[22]
Drasar PB, Khripach VA. Growing importance of natural products research. Molecules 2019; 25(1): 6.
[http://dx.doi.org/10.3390/molecules25010006] [PMID: 31861374]
[23]
Mushtaq S, Abbasi BH, Uzair B, Abbasi R. Natural products as reservoirs of novel therapeutic agents. EXCLI J 2018; 17: 420-51.
[PMID: 29805348]
[24]
Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT, Banach M, Rollinger JM, et al. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov 2021; 20(3): 200-16.
[http://dx.doi.org/10.1038/s41573-020-00114-z] [PMID: 33510482]
[25]
Demain AL, Vaishnav P. Natural products for cancer chemotherapy. Microb Biotechnol 2011; 4(6): 687-99.
[http://dx.doi.org/10.1111/j.1751-7915.2010.00221.x] [PMID: 21375717]
[26]
Dong S, Guo X, Han F, He Z, Wang Y. Emerging role of natural products in cancer immunotherapy. Acta Pharm Sin B 2022; 12(3): 1163-85.
[http://dx.doi.org/10.1016/j.apsb.2021.08.020] [PMID: 35530162]
[27]
Talib WH, Alsayed AR, Barakat M, Abu-Taha MI, Mahmod AI. Targeting drug chemo-resistance in cancer using natural products. Biomedicines 2021; 9(10): 1353.
[http://dx.doi.org/10.3390/biomedicines9101353] [PMID: 34680470]
[28]
Rayan A, Raiyn J, Falah M. Nature is the best source of anticancer drugs: Indexing natural products for their anticancer bioactivity. PLoS One 2017; 12(11): e0187925.
[http://dx.doi.org/10.1371/journal.pone.0187925] [PMID: 29121120]
[29]
Prakash O, Kumar A, Kumar P, Ajeet A. Anticancer potential of plants and natural products: A review. Am J Pharmacol Sci 2013; 1(6): 104-15.
[http://dx.doi.org/10.12691/ajps-1-6-1]
[30]
U.S. Code § 154 - Contents and term of patent; provisional rights | U.S. Code | US Law | LII /Legal Information Institute. Available from: https://www.law.cornell.edu/uscode/text/35/154 [Accessed on: 22 Dec 2021].
[31]
Bhattacharya S, Saha CN. Intellectual property rights: An overview and implications in pharmaceutical industry. J Adv Pharm Technol Res 2011; 2(2): 88-93.
[http://dx.doi.org/10.4103/2231-4040.82952] [PMID: 22171299]
[32]
Stjepandić J, Liese H, Trappey AJC. Intellectual property protection. Concurr Eng 21st Century Found Dev Challenges 2015; 8(10): 521-1.
[http://dx.doi.org/10.1007/978-3-319-13776-6_18]
[33]
Kumar V. Patent filing and drafting procedure in india for a new pharmaceutical product. Innoriginal Int J Sci 2018; 5(4): 13-6.
[34]
Murudkar S. Should Researchers Publish or Patent First?. Enago Academy 2021. Available from: https://www.enago.com/academy/publish-or-patent-first/ [Accessed on: 22 Dec 2021].
[35]
Australia IP. IP Australia. Patent basics | IP Australia 2018. Available from: https://www.ipaustralia.gov.au/patents/understandingpatents/patent-basics [Accessed on: 22 Dec 2021].
[36]
International Patent Classification. Available from: https://www.wipo.int/classifications/ipc/en/ [Accessed on: 22 Dec 2021].
[37]
EPO - Cooperative Patent Classification (CPC). Available from: https://www.epo.org/searching-for-patents/helpful-resources/firsttime-here/classification/cpc.html [Accessed on: 22 Dec 2021].
[38]
Patent Classification, USPTO. Office of Patent Classification. 2019. Available from: https://www.uspto.gov/patents/search/classificationstandards-and-development [Accessed on: 22 Dec 2021].
[39]
USPTO classification resource; Cooperative Patient Classification-Chemistry; Metallurgy 2021. Available from: https://www.uspto.gov/web/patents/classification/cpc/html/cpc-C.html [Accessed on: 22 Dec 2021].
[40]
USPTO classification resource; Cooperative Patent Classification Human Necessities 2021. Available from: https://www.uspto.gov/web/patents/classification/cpc/html/cpc-A.html [Accessed on: 22 Dec 2021].
[41]
Bressmann T. Self-inflicted cosmetic tongue split: A case report. J Can Dent Assoc 2004; 70(3): 156-7.
[PMID: 15003161]
[42]
U.S. Food & Drug Administration. Botanical Drug Development - Guidance for industry. U.S. Department of Health and Human Services. 2016. Available from: https://www.fda.gov/files/drugs/published/Botanical-Drug-Develop ment-Guidance-for-Industry.pdf [Accessed on: 22 Dec 2021].
[43]
Shabbir M, Love J, Montgomery B. Phase I trial of PC-Spes2 in advanced hormone refractory prostate cancer. Oncol Rep 2008; 19(3): 831-5.
[http://dx.doi.org/10.3892/or.19.3.831] [PMID: 18288423]
[44]
Guns ES, Goldenberg SL, Brown PN. Mass spectral analysis of PC-SPES confirms the presence of diethylstilbestrol. Can J Urol 2002; 9(6): 1684-8.
[PMID: 12517310]
[45]
Blumenthal M. The rise and fall of PC-SPES: new generation of herbal supplement, adulterated product, or new drug? Integr Cancer Ther 2002; 1(3): 266-70.
[http://dx.doi.org/10.1177/153473540200100311] [PMID: 14667284]
[46]
DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998; 339(12): 785-91.
[http://dx.doi.org/10.1056/NEJM199809173391201] [PMID: 9738085]
[47]
Newmaster SG, Grguric M, Shanmughanandhan D, Ramalingam S, Ragupathy S. DNA barcoding detects contamination and substitution in North American herbal products. BMC Med 2013; 11(1): 222.
[http://dx.doi.org/10.1186/1741-7015-11-222] [PMID: 24120035]
[48]
Patent vs Research Paper Publication - Intellectual Property - India 2020. Available from: https://www.mondaq.com/india/patent/907012/patent-vs-researchpaper-publication [Accessed on: 22 Dec 2021].
[49]
Paller CJ, Denmeade SR, Carducci MA. Challenges of conducting clinical trials of natural products to combat cancer. Clin Adv Hematol Oncol 2016; 14(6): 447-55.
[PMID: 27379814]
[50]
Lal R. Patents and Exclusivity. FDA/CDER SBIA Chronicles 2015. Available from: https://www.fda.gov/media/92548/download [Accessed on: 5 Jul 2022].
[51]
Patent Expiry Date Definition | Law Insider. Available from: https://www.lawinsider.com/dictionary/patent-expiry-date [Accessed on: 5 Jul 2022].
[52]
Sajewycz MW. Patent protection strategies. Sohn International Symposium. 125-32.
[53]
Marketing Exclusivity for Drug Developers: What is it & Different Types. Available from: https://www.nuventra.com/resources/blog/types-of-marketing-exclusivity/ [Accessed on: 5 Jul 2022].
[54]
Russo AH. Association for Molecular Pathology v. Myriad Genetics, Inc. and Its Impact on the Patentability of Designer Genes. New York Univ J Intellect Prop Entertain Law 2014; 4 Available from: http://heinonline.org/HOL/Page?handle=hein.journals/nyuinpe4&div=7&collection=journals&set_as_cursor=69&men_tab=srchresults&terms=brca1%7Cand%7Cintellectual%7Cproperty&type=matchall%5Cnhttp://heinonline.org/HOL/Page?handle=hein.journals/nyui npe4&div=7&col
[55]
Kingston DGI, Molinero AA, Gunatilaka AAL. Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol. Patent US5470866A, 1995.
[56]
Paul HJ, Andrew RP. Topoisomerase inhibitors with antibacterial and anticancer activity. Patent US11274106B2, 2020.
[57]
Kinghorn AD, Ren Y, Chai H, et al. Arylnaphthalene lactone derivatives and methods of making and using thereof. Patent US20170119806A1, 2017.
[58]
Subbiah V. Method of isolating cucurbitacin. Patent US5925356A, 1999.
[59]
Hung K, Xing H. Method of inducing apoptosis in cancer treatment by using cucurbitacins. US20080207578A1, 2007.
[60]
Wang CC, Chen LG, Chang TL, Hsieh CT. Extracts of aquilaria hulls and use thereof in the treatment of cancer. Patent US20110160152A1, 2011.
[61]
Jianhua J, Yongxiang S, Jie L, Hongbo H. Angucycline compounds and application of angucycline compounds in preparation of anti-tumour or antibacterial medicine. Patent CN104744533A, 2015.
[62]
Jianhua J, Yongxiang S, Hongbo H, Yan Z. Phenazine compound and it application in preparation of anti-tumor drugs. Patent CN103360329A, 2013.
[63]
Wang F, Zhang Q, Huang Z, Xinpeng T, Jie L. Sulfur-containing diindolyl diketopiperazine compounds and application thereof in preparing antineoplastic drugs. Patent CN102911188A, 2013.
[64]
Caijuan Z, Guolei H, Meng B, Guangying C, Youping L, Xueming Z. A kind of indoles diterpene-kind compound of mangrove xylocarpus granatum originated from fungus and preparation method and application. Patent CN107827805A, 2018.
[65]
Zhihong X, Yuhui Z, Hui W, Xiaomin W. Novel sea asparagus triterpenoid saponin reducing compound as well as preparation method and application thereof. Patent CN103304622A, 2013.
[66]
Tongyoung Z, Guotai Z. New sesquiterpene quinine compound in dysidea avara and application thereof. Patent CN104478688A, 2014.
[67]
Shujuan P, Houwen L, Haiyan L, Fan Y, Wansheng C. The black amber terpene of sesterterpene compounds I and its production and use. Patent CN102617596B, 2016.
[68]
Amin A. Prevention of Liver Cancer with Safranal-Based Formulations. Patent WO2020174446A1, 2020.
[69]
Amin A, Awad B. Crocin-sorafenib combination therapy for liver cancer. Patent WO2021009706A2, 2021.
[70]
Topotecan - GlaxoSmithKline - AdisInsight Available from: https://adisinsight.springer.com/drugs/800000829 [Accessed on: 22 Dec 2021].
[71]
GlaxoSmithKline Says FDA Gives Cancer Drug Hycamtin Priority Review | BioSpace. Available from: https://www.biospace.com/article/releases/glaxosmithkline-saysfda-gives-cancer-drug-hycamtin-priority-review-/ [Accessed on: 22 Dec 2021].
[72]
Dasiglucagon: Uses, Interactions, Mechanism of Action | Drug-Bank. Available from: https://go.drugbank.com/drugs/DB12459 [Accessed on: 22 Dec 2021].
[73]
Norepinephrine: Uses, Interactions, Mechanism of Action | Drug-Bank. Available from: https://go.drugbank.com/drugs/DB04690 [Accessed on: 22 Dec 2021].
[74]
Miyasaka T, Sawada S, Nokata K, Mutai M. Photochemical process for preparing camptothecin derivatives. Patent US4545880A, 2021.
[75]
Dasiglucagon: Uses, Interactions, Mechanism of Action | Drug-Bank. Available from: https://go.drugbank.com/drugs/DB00987 [Accessed on: 22 Dec 2021].
[76]
Dyshlovoy SA, Honecker F. Marine compounds and cancer: The first two decades of XXI century 2019; 18(1): 20.
[77]
MicroBio Group. MICROBIO GROUP. 2016. Available from: https://www.microbio.com.tw/home_03.php?p=7&a=10 [Accessed on: 22 Dec 2021].
[78]
Omacetaxine mepesuccinate: Uses, Interactions, Mechanism of Action | DrugBank Available from: https://go.drugbank.com/drugs/DB04865 Accessed on: 22 Dec 2021.
[79]
Anticancer agent HALAVEN® approved for treatment of locally advanced or metastatic breast cancer in China, News Release 2019, Eisai Co., Ltd. 2019. Available from: https://www.eisai.com/news/2019/news201952.html [Accessed on: 22 Dec 2021].
[80]
Devriese LA, Witteveen PO, Marchetti S, et al. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemother Pharmacol 2012; 70(6): 823-32.
[http://dx.doi.org/10.1007/s00280-012-1976-x] [PMID: 23010853]
[81]
Shablak A. Eribulin for advanced breast cancer: a drug evaluation. J Breast Cancer 2013; 16(1): 12-5.
[http://dx.doi.org/10.4048/jbc.2013.16.1.12] [PMID: 23593076]
[82]
Eribulin mesylate - Eisai Co Ltd - AdisInsight Available from: https://adisinsight.springer.com/drugs/800015511 [Accessed on: 22 Dec 2021].
[83]
Treatment with YONDELIS® (trabectedin) | HCP. Available from: https://www.yondelis.com/ [Accessed on: 22 Dec 2021].
[84]
Ingenol mebutate - LEO Pharma - AdisInsight. Available from: https://adisinsight.springer.com/drugs/800021682 [Accessed on: 22 Dec 2021].
[85]
LEO Pharma to Acquire Peplin Inc. for $287.5 Million | BioSpace. Available from: https://www.biospace.com/article/releases/leopharma- to-acquire-peplin-inc-for-287-5-million-/ [Accessed on: 22 Dec 2021].
[86]
Irinotecan - Yakult Honsha - AdisInsight. Available from: https://adisinsight.springer.com/drugs/800000748 [Accessed on: 22 Dec 2021].
[87]
MacConnachie AM. Docetaxel (taxotere, Rhone-Poulenc Rorer). Intensive & critical care nursing : the official journal of the British Association of Critical Care Nurses 1997; 13(2): 119-20.
[88]
VanderMolen KM, McCulloch W, Pearce C, Oberlis NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, Depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma. Available from: http://libres.uncg.edu/ir/uncg/f/N_Oberlies_Romidepsin_2011.pdf [Accessed on: 22 Dec 2021].
[89]
Story S. Success Story: Taxol. National Cancer Institute 2018. Available from: https://dtp.cancer.gov/timeline/flash/success_stories/s2_taxol.htm[Accessed on: 22 Dec 2021].
[90]
SYNRIBO (omacetaxine mepesuccinate) | Healthcare Professional Site. Available from: https://www.synribohcp.com/ [Accessed on: 22 Dec 2021].
[91]
Zinostatin stimalamer - AdisInsight. Available from: https://adisinsight.springer.com/drugs/800001078[Accessed on: 22 Dec 2021].
[92]
History of the Former Yamanouchi Pharmaceutical Co., Ltd. Astellas Pharma Inc. Available from: https://www.astellas.com/en/about/history-of-yamanouchi [Accessed on: 22 Dec 2021].
[93]
Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med 2017; 6(1): 44.
[http://dx.doi.org/10.1186/s40169-017-0175-0] [PMID: 29230567]
[94]
SIZOFIRAN. Available from: https://drugs.ncats.io/drug/7F763NNC9X [Accessed on: 22 Dec 2021].
[95]
Kony DB, Damm W, Stoll S, van Gunsteren WF, Hünenberger PH. Explicit-solvent molecular dynamics simulations of the polysaccharide schizophyllan in water. Biophys J 2007; 93(2): 442-55.
[http://dx.doi.org/10.1529/biophysj.106.086116] [PMID: 17237195]
[96]
Sizofiran - AdisInsight Available from: http://adisinsight.springer.com/drugs/800002019 [Accessed on: 22 Dec 2021].
[97]
Steinhagen H. The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. By Enrique Raviña. ChemMedChem 2011; 6(9): 1746-7.
[http://dx.doi.org/10.1002/cmdc.201100321]
[98]
Hadfield JA, Ducki S, Hirst N, McGown AT. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 2003; 5: 309-25.
[PMID: 14593726]
[99]
Xu H, Lv M, Tian X. A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007. Curr Med Chem 2009; 16(3): 327-49.
[http://dx.doi.org/10.2174/092986709787002682] [PMID: 19149581]
[100]
Shah Z, Gohar UF, Jamshed I, et al. Podophyllotoxin: History, recent advances and future prospects. Biomolecules 2021; 11(4): 603.
[http://dx.doi.org/10.3390/biom11040603] [PMID: 33921719]
[101]
Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998; 34(10): 1514-21.
[http://dx.doi.org/10.1016/S0959-8049(98)00228-7] [PMID: 9893622]
[102]
Kuhn M, Von Wartbung A. Podophyllum- Lignane: Struktur und Absolutkonfiguration von Podorhizol-?-D-glucosid (= Lignan F). 19. Mitt. über mitosehemmende Naturstoffe [1]. Helv Chim Acta 1967; 50(6): 1546-65.
[http://dx.doi.org/10.1002/hlca.19670500614]
[103]
Company History Timeline - Bristol Myers Squibb. Available from: https://www.bms.com/about-us/our-company/historytimeline.html [Accessed on: 22 Apr 2022].
[104]
Hollstein U. Actinomycin. Chemistry and mechanism of action. Chem Rev 1974; 74(6): 625-52.
[http://dx.doi.org/10.1021/cr60292a002]
[105]
Waksman SA, Woodruff HB. Bacteriostatic and Bactericidal Substances Produced by a Soil Actinomyces. Exp Biol Med 1940; 45(2): 609-14.
[http://dx.doi.org/10.3181/00379727-45-11768]
[106]
Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 1967; 20(3): 333-53.
[http://dx.doi.org/10.1002/1097-0142(1967)20:3<333:AID-CNCR2820200302>3.0.CO;2-K] [PMID: 4290058]
[107]
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547852/ [Accessed on: 5 Jul 2022].
[108]
Duration of Patent Protection Under. Available from: https://www.justia.com/intellectual-property/patents/duration-ofpatent- protection/ [Accessed on: 5 Jul 2022].
[109]
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm? Product_No=001&Appl_No=020981&Appl_type=N [Accessed on: 5 Jul 2022].
[110]
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm? Product_No=001&Appl_No=202833&Appl_type=N [Accessed on: 5 Jul 2022].
[111]
He JZ. UK: Genericsweb Analyses Opportunity For Generic Docetaxel. Available from: https://www.mondaq.com/uk/patent/122882/genericswebanalyses-opportunity-for-generic-docetaxel [Accessed on: 5 Jul 2022].
[112]
Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations. Available from:https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=203585&Appl_type=N [Accessed on: 5 Jul 2022].
[113]
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Pr oduct_No=001&Appl_No=201532&Appl_type=N [Accessed on: 5 Jul 2022].
[114]
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Pr oduct_No=001&Appl_No=209401&Appl_type=N [Accessed on: 5 Jul 2022].
[115]
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=021660&Appl_type=N [Accessed on: 5 Jul 2022].
[116]
United States securities and exchange commission Washington, D.C. 20549, Form 10-K, Celgene Corporation. 2018. Available from: https://www.sec.gov/Archives/edgar/data/816284/000104746912001293/a2207399z10-k.htm#:~:text=The [Accessed on: 5 Jul 2022].
[117]
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=201023&Appl_type=N [Accessed on: 5 Jul 2022].
[118]
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=207793&Appl_type=N [Accessed on: 5 Jul 2022].
[119]
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=022088&Appl_type=N [Accessed on: 5 Jul 2022].
[120]
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=002&Appl_No=022065&Appl_type=N [Accessed on: 5 Jul 2022].
[121]
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=207953&Appl_type=N [Accessed on: 5 Jul 2022].
[122]
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=003&Appl_No=202714&Appl_type=N [Accessed on: 5 Jul 2022].
[123]
Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, et al. Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv 2015; 33(8): 1582-614.
[http://dx.doi.org/10.1016/j.biotechadv.2015.08.001] [PMID: 26281720]
[124]
Romano JD, Tatonetti NP. Informatics and computational methods in natural product drug discovery: A review and perspectives. Front Genet 2019; 10: 368.
[http://dx.doi.org/10.3389/fgene.2019.00368] [PMID: 31114606]
[125]
Cech NB, Medema MH, Clardy J. Benefiting from big data in natural products: importance of preserving foundational skills and prioritizing data quality. Nat Prod Rep 2021; 38(11): 1947-53.
[http://dx.doi.org/10.1039/D1NP00061F] [PMID: 34734219]
[126]
Leelananda SP, Lindert S. Computational methods in drug discovery. Beilstein J Org Chem 2016; 12(1): 2694-718.
[http://dx.doi.org/10.3762/bjoc.12.267] [PMID: 28144341]

Rights & Permissions Print Cite
Article Metrics
49
2
© 2024 Bentham Science Publishers | Privacy Policy